11:42 AM EDT, 06/13/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday JNJ-90014496 showed "encouraging" results in the first clinical data from an ongoing phase 1b study in relapsed or refractory large B-cell lymphoma.

The study showed 75% to 80% complete response rate among evaluable patients at the recommended phase 2 dose, it said.

"The data...show encouraging clinical activity and promising safety, and represent a step forward in delivering a potential new treatment option to patients living with the most common type of aggressive lymphoma," said principal investigator Krish Patel.

Price: 157.07, Change: +0.41, Percent Change: +0.26